Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

L1CAM as a candidate therapeutic target in small-cell neuroendocrine prostate cancer

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Alexandra Corella

Citation

Annals of Oncology (2020) 31 (suppl_1): S10-S13. 10.1016/annonc/annonc85

Authors

A.N. Corella, T. Pariva, I. Coleman, J.K. Lee, P.S. Nelson

Author affiliations

  • Human Biology, Fred Hutchinson Cancer Research Center, 98109 - Seattle/US
More

Resources

Small-cell neuroendocrine prostate cancer (SCNPC) is an aggressive variant form of prostate cancer that is resistant to androgen receptor(AR)-directed targeted therapies. SCNPC has molecular and morphological features in common with other aggressive small-cell tumors such as small-cell lung cancer (SCLC) and Merkel cell carcinoma (MCC). We recently conducted a pan-cancer transcriptomic analysis to identify “druggable” targets that display conserved expression patterns across small-cell tumors. Using this method, we identified and subsequently determined that BCL2 inhibitors (BCL2i) are lethal in SCNPC cell lines and repress the growth of a subset of SCNPC patient-derived xenograft models (PDXs). In this study, we profile the expression of an additional candidate target identified by this method, L1CAM.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings